An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients

NCT01453049 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

86

Enrollment

INDUSTRY

Sponsor class

Stopped US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: rosiglitazone/glimepiride fix dose combination
DRUG: glimepiride

Sponsor

GlaxoSmithKline